PIGMENTATION DISORDERS TREATMENT MARKET ANALYSIS

Pigmentation Disorders Treatment Market, By Disorder Type (Melasma, Vitiligo, Albinism, Post-Inflammatory Hyperpigmentation (PIH), and Others), By Drug Type (Corticosteroids, Calcineurin Inhibitors, Janus kinase inhibitor, Melanin Synthesis Inhibitor, and Others), By Route of Administration (Oral, Topical, and Other), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Feb 2025
Code : CMI5421
Pages :172
Formats :
Excel and PDF
Industry : Pharmaceutical

Pigmentation Disorders Treatment Market Size and Trends

The global pigmentation disorders treatment market is estimated to be valued at USD 8.01 Bn in 2025 and is expected to reach USD 14.94 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 9.3% from 2025 to 2032.

Pigmentation Disorders Treatment Market Key Factors

To learn more about this report, Request sample copy

The global pigmentation disorders treatment market is experiencing strong growth due to the rise in prevalence of pigmentation disorders and growing geriatric population across the world. Moreover, rise in demand for safe & effective treatment and increasing awareness among people about pigmentation disorders is expected to boost the growth of the market. However, factors such as high cost associated with treatment and lack of reimbursement policies are expected to hamper growth of the global pigmentation disorders treatment market.

Market Driver – Increasing Prevalence of Pigmentation Disorders

The increasing prevalence of pigmentation disorders such as vitiligo across the globe is expected to augment the growth of the global pigmentation disorders treatment market over the forecast period. For instance, according to an article published in JAMA Network, an open access medical journal published by the American Medical Association, in November 2021, a survey was conducted on people living in the U.S. in 2020, and the study demonstrated that the prevalence of vitiligo in adults was between 0.76% (1.9 million cases in 2020) and 1.11% (2.8 million cases in 2020). Additionally, according to the same source, around 40% of adult vitiligo in the U.S. may be undiagnosed.